Published in J Clin Microbiol on May 30, 2007
Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis (2009) 1.49
Underascertainment of acute hepatitis C virus infections in the U.S. surveillance system: a case series and chart review. Ann Intern Med (2015) 1.48
Visceral adiposity index: an indicator of adipose tissue dysfunction. Int J Endocrinol (2014) 1.05
Hepatitis C in HIV-infected individuals: cure and control, right now. J Int AIDS Soc (2011) 1.03
Sex differences in HIV RNA level and CD4 cell percentage during childhood. Clin Infect Dis (2011) 0.99
Highly divergent hepaciviruses from African cattle. J Virol (2015) 0.84
Metabolic factors and chronic hepatitis C: a complex interplay. Biomed Res Int (2013) 0.82
Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma Risk. Sci Rep (2015) 0.77
Influence of IFNL3 and HLA-DPB1 genotype on postpartum control of hepatitis C virus replication and T-cell recovery. Proc Natl Acad Sci U S A (2016) 0.76
Correlates of high hepatitis C virus RNA load in a cohort of HIV-negative and HIV-positive individuals with haemophilia. J Viral Hepat (2011) 0.76
Visceral Adiposity Index and the Degree of Hepatic Fibrosis and Inflammation in Egyptian Patients with Chronic Hepatitis C. J Clin Diagn Res (2017) 0.75
HCV Ag quantification as a one-step procedure in diagnosing chronic hepatitis C infection in Cameroon: the ANRS 12336 study. J Int AIDS Soc (2017) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40
Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology (1982) 11.24
The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA (2000) 7.65
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med (1998) 6.23
Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med (2000) 5.58
Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis (1995) 5.53
A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med (1991) 4.79
Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology (1999) 4.59
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med (2000) 3.74
Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev (2000) 3.70
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 3.47
Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region. J Gen Virol (1995) 3.10
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology (2001) 3.02
Variation of the hepatitis C virus 5' non-coding region: implications for secondary structure, virus detection and typing. The International HCV Collaborative Study Group. J Gen Virol (1995) 2.91
High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology (2003) 2.60
Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis (2001) 2.47
Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem (2000) 2.47
Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection. Gut (1998) 2.45
Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem (2000) 2.30
Host genetic factors influence disease progression in chronic hepatitis C. Hepatology (2000) 2.26
Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology (2003) 2.23
Use and interpretation of virological tests for hepatitis C. Hepatology (2002) 1.92
Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun (2003) 1.88
Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology (1998) 1.84
HLA-Cw*04 and hepatitis C virus persistence. J Virol (2002) 1.83
Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol (1999) 1.80
Chronic viral hepatitis and the human genome. Hepatology (2000) 1.79
Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology (1999) 1.79
Hepatitis C virus genotyping: interrogation of the 5' untranslated region cannot accurately distinguish genotypes 1a and 1b. J Clin Microbiol (2002) 1.78
Multicenter evaluation of hepatitis C RNA levels among female injection drug users. J Infect Dis (2001) 1.77
Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. J Infect Dis (1994) 1.71
Hepatitis C virus subtyping by a core-envelope 1-based reverse transcriptase PCR assay with sequencing and its use in determining subtype distribution among Danish patients. J Clin Microbiol (2003) 1.67
Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology (2006) 1.63
Clinical evaluation of two methods for genotyping hepatitis C virus based on analysis of the 5' noncoding region. J Clin Microbiol (2003) 1.62
Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. J Hepatol (2006) 1.60
Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis (1996) 1.53
Standardization of hepatitis C virus RNA quantification. Hepatology (2000) 1.52
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology (2001) 1.49
Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study. J Clin Microbiol (2005) 1.45
Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol (1993) 1.40
Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology (2002) 1.35
Determinants of the quantity of hepatitis C virus RNA. J Infect Dis (2000) 1.32
Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology (1993) 1.31
Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics (2003) 1.30
Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut (2003) 1.23
Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat (1996) 1.21
Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis (2006) 1.19
The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr (2003) 1.19
Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection. Genes Immun (2002) 1.09
Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies. J Virol (2001) 1.08
The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology (1999) 1.08
Chronic hepatitis C in African Americans and other minority groups. Curr Gastroenterol Rep (2004) 1.07
Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology (2005) 1.05
Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology (2001) 1.05
Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol (1998) 1.02
Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J Hepatol (1999) 0.97
Detection of genomic- and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reverse-transcriptase polymerase chain reaction. Hepatology (1999) 0.97
Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol (2004) 0.95
Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C. J Gastroenterol (2000) 0.93
Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J Viral Hepat (2001) 0.92
Fluctuation of serum HCV-RNA levels in untreated blood donors with chronic hepatitis C virus infection. J Viral Hepat (2002) 0.90
Natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study. Hepatology (2000) 0.88
Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. Hepatology (1998) 0.87
Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity? Hepatology (1999) 0.86
Use of diagnostic testing for managing hepatitis C virus infection. Semin Liver Dis (2004) 0.85
MHC and the viral hepatitides. QJM (2001) 0.85
Fluctuations of hepatitis C virus load are not related to amino acid substitutions in hypervariable region 1 and interferon sensitivity determining region. J Med Virol (1999) 0.84
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis (2004) 6.13
Protection against persistence of hepatitis C. Lancet (2002) 5.94
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60
Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06
Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A (2006) 4.54
Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med (2009) 4.21
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15
Occult hepatitis B. Lancet Infect Dis (2002) 3.09
Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
In vivo imaging of glucose uptake and metabolism in tumors. Nat Med (2013) 3.01
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71
Hepatitis C in the HIV-Infected Person. Ann Intern Med (2003) 2.67
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
Needlestick transmission of hepatitis C. JAMA (2002) 2.55
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34
Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24
High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther (2011) 2.20
Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med (2005) 2.16
Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology (2012) 2.14
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol (2006) 2.12
Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis (2005) 2.02
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92
Cross-genotype immunity to hepatitis C virus. J Virol (2004) 1.92
Hepatitis C virus infection and incident type 2 diabetes. Hepatology (2003) 1.89
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA (2012) 1.88
HLA-Cw*04 and hepatitis C virus persistence. J Virol (2002) 1.83
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS (2006) 1.82
Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis (2009) 1.80
Changes in blood-borne infection risk among injection drug users. J Infect Dis (2011) 1.74
Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology (2002) 1.65
Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology (2006) 1.63
Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health (2004) 1.62
Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis (2003) 1.57
Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology (2010) 1.53
Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J Virol (2003) 1.52
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS (2004) 1.44
Serum albumin as a prognostic indicator for HIV disease progression. AIDS Res Hum Retroviruses (2006) 1.42
Prospective study of infective endocarditis among injection drug users. J Infect Dis (2002) 1.41
Discordance between CD4+ T-lymphocyte counts and percentages in HIV-infected persons with liver fibrosis. Clin Infect Dis (2012) 1.41
HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med (2013) 1.41
Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. Gastroenterology (2006) 1.38
Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med (2004) 1.36
High HCV seroprevalence and HIV drug use risk behaviors among injection drug users in Pakistan. Harm Reduct J (2006) 1.36
Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology (2002) 1.35
Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol (2004) 1.34
Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology (2014) 1.29
CD4+ T cell depletion in an untreated HIV type 1-infected human leukocyte antigen-B*5801-positive patient with an undetectable viral load. Clin Infect Dis (2008) 1.29
Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis (2010) 1.28
Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection. Drug Alcohol Depend (2004) 1.28
High frequency of false-positive hepatitis C virus enzyme-linked immunosorbent assay in Rakai, Uganda. Clin Infect Dis (2013) 1.26
Accurate representation of the hepatitis C virus quasispecies in 5.2-kilobase amplicons. J Clin Microbiol (2004) 1.26
A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci U S A (2007) 1.24
Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver. Gastroenterology (2013) 1.23
High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology (2004) 1.23
Association of CTLA4 polymorphism with regulatory T cell frequency. Eur J Immunol (2005) 1.22
Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology (2012) 1.20
The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr (2003) 1.19
Mannose binding lectin genotypes influence recovery from hepatitis B virus infection. J Virol (2005) 1.19
Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus. J Infect Dis (2013) 1.18
Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence. J Virol (2006) 1.17
The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology (2005) 1.17
High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Drug Alcohol Depend (2005) 1.17
Epistatic effects of immunoglobulin GM and KM allotypes on outcome of infection with hepatitis C virus. J Virol (2004) 1.16
The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr (2003) 1.13
CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C. J Infect Dis (2011) 1.12
Screening for HCV infection in jails. JAMA (2012) 1.11
Predictors and effects of alcohol use on liver function among young HCV-infected injection drug users in a behavioral intervention. J Hepatol (2010) 1.10
Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. J Clin Virol (2007) 1.10
Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology (2014) 1.08
The chronic vascular and haemodynamic response after permanent bilateral common carotid occlusion in newborn and adult rats. J Cereb Blood Flow Metab (2006) 1.07
Design and feasibility of a randomized behavioral intervention to reduce distributive injection risk and improve health-care access among hepatitis C virus positive injection drug users: the Study to Reduce Intravenous Exposures (STRIVE). J Urban Health (2007) 1.06
High-resolution functional MRI at 3 T: 3D/2D echo-planar imaging with optimized physiological noise correction. Magn Reson Med (2012) 1.05
Genetic polymorphism in IL28B is associated with spontaneous clearance of hepatitis C virus genotype 4 infection in an Egyptian cohort. J Infect Dis (2011) 1.04
Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis (2008) 1.04
High plasma interleukin-18 levels mark the acute phase of hepatitis C virus infection. J Infect Dis (2011) 1.04
Risk factors for hepatitis C virus infection among blood donors in northern Thailand. Transfusion (2004) 1.03
Hepatitis C in the HIV-infected patient. Clin Liver Dis (2003) 1.03
HCV reinfection studies and the door to vaccine development. J Hepatol (2009) 1.02
CD4+ T cell-dependent reduction in hepatitis C virus-specific humoral immune responses after HIV infection. J Infect Dis (2007) 1.01
Detection of microbial translocation in HIV and SIV infection using the Limulus amebocyte lysate assay is masked by serum and plasma. PLoS One (2012) 1.01
Risk factors for Kaposi's sarcoma-associated herpesvirus infection among HIV-1-infected pregnant women in the USA. AIDS (2003) 1.00
Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology (2012) 1.00